Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted ...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...

Twenty-one companies in the healthcare sector released their quarterly results in the week ending August 1. With this, over ...

Biotech company Biogen (NASDAQ:BIIB) in Q2 CY2025, with sales up 7.3% year on year to $2.65 billion. Its non-GAAP profit of ...

Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Thursday morning. Here’s what you need to know. Biogen ...

Q2 2025 Earnings Call Transcript July 31, 2025 Biogen Inc. misses on earnings expectations. Reported EPS is $ EPS, ...

What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) fell 3.1% in the morning session after analysts at Truist ...

Eisai (OTCPK:ESALF) and Eli Lilly (NYSE:LLY) on Wednesday announced data from long-term extension studies for their ...

Biogen Inc. (NASDAQ:BIIB) ranks among the stocks to benefit from an onshoring boom. On July 21, Biogen Inc. (NASDAQ:BIIB) declared that it would invest $2 billion to its existing North Carolina ...

Biogen (NASDAQ:BIIB) is scheduled to announce Q2 earnings results on Thursday, July 31st, before market open. The consensus EPS Estimate is $3.88 (-3.5% Y/Y) and the consensus Revenue Estimate is ...